GlaxoSmithKline Pharmaceuticals Limited will hold a meeting of the Board of Directors on November 6, 2025, to consider and approve the un-audited financial results for the second quarter (Q2 – July to September) and half-year ended September 30, 2025. This announcement follows regulations concerning disclosure requirements. The results will provide insights into the company’s financial performance during this period.
Board Meeting Announcement
A meeting of the Board of Directors of GlaxoSmithKline Pharmaceuticals Limited is scheduled for November 6, 2025. The primary purpose of this meeting is to review and approve the company’s un-audited financial results.
Financial Results Under Review
The financial results under consideration pertain to the second quarter (Q2 – July to September) and the half-year period, both ending on September 30, 2025. Upon approval, these results will provide detailed insights into the company’s performance over these periods.
Source: BSE
